[Pioglitazone in evaluation by IQWiG (Institute for Quality and Cost Effectiveness in Public Health)--tunnel vision instead of broad view].
出版信息
MMW Fortschr Med. 2008 Aug 28;150(32-35):56-7.
PMID:19009700
Abstract
摘要
相似文献
1
[Pioglitazone in evaluation by IQWiG (Institute for Quality and Cost Effectiveness in Public Health)--tunnel vision instead of broad view].
MMW Fortschr Med. 2008 Aug 28;150(32-35):56-7.
2
[Too positive comment on glitazones].
Ugeskr Laeger. 2007 Feb 19;169(8):733; author reply 733.
3
The Avandia debate: an unhappy conclusion.
J Diabetes. 2010 Dec;2(4):221-2. doi: 10.1111/j.1753-0407.2010.00096.x.
4
[Insulin resistance increases risk of infarct. Glitazone now approved also for monotherapy].
MMW Fortschr Med. 2003 Sep 18;145(38):61.
5
[How does the PROactive Study change therapy of diabetes?].
MMW Fortschr Med. 2005 Oct 13;147(41):6.
6
[Rosiglitazone--statistics for benefits and problems].
Tidsskr Nor Laegeforen. 2007 Oct 18;127(20):2702-3.
7
[Glitazones critically evaluated].
Dtsch Med Wochenschr. 2007 Dec;132(49):2619. doi: 10.1055/s-2007-993106.
8
[The benefit of pioglitazone in patients with diabetes mellitus type 2 and cardiovascular complications].
Vnitr Lek. 2005 Dec;51(12):1412.
9
[The effect of glitazones on the progression of type 2 diabetes and on cardiovascular endpoints].
Dtsch Med Wochenschr. 2005 Aug 5;130(31-32):1825-30. doi: 10.1055/s-2005-871905.
10
[DMP recommends only 4 antidiabetic drugs. When may different prescriptions be allowed?].
MMW Fortschr Med. 2003 Sep 18;145(38):62.
Zotero 插件